Marshall Wace, LLP Karuna Therapeutics, Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$161.01 - $317.85 $1.83 Million - $3.61 Million	11,359 New	11,359 $3.6 Million
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $11.7 Million - $14.4 Million	-60,905 Reduced 98.06%	1,207 $237,000
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $1.43 Million - $3.2 Million	11,531 Added 22.8%	62,112 $14 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $4.02 Million - $6.14 Million	42,821 Added 551.82%	50,581 $6.4 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $450,984 - $603,607	4,560 Added 142.5%	7,760 $983,000
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $354,048 - $510,080	3,200 New	3,200 $419,000
Q2 2021 Aug 13, 2021	SELL	$107.45 - $135.95 $4.93 Million - $6.23 Million	-45,861 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $4.38 Million - $6.1 Million	45,861 New	45,861 $5.52 Million
Q2 2020 Aug 13, 2020	SELL	$62.14 - $117.21 $64,252 - $121,195	-1,034 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$60.41 - $115.92 $62,463 - $119,861	1,034 New	1,034 $74,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.